The world’s largest Rheumatology meeting, the American College of Rheumatology's Annual Meeting (ACR/ARHP 2018), took place last month (Oct. 20-23) in Chicago. The meeting brought together more than 15,000 advocates, healthcare providers and researchers to advance care for patients.
Popular session topics included updated classification criteria for large vessel vasculitis...
Primary immunodeficiency disorders have a growing spectrum of noninfectious complications that includes vasculitis: #ACR18 https://t.co/3qMJGFAXgB— Cleveland Clinic MD (@CleClinicMD) October 23, 2018
#Vasculitis oral abstract session at #ACR18: back to back abstracts on use of #leflunomide for #GCA and #PMR. Promising results on efficacy and #steroid sparing effect. Could it become a standard alternative when tocilizumab contraindicated or not available?— Angelo Gaffo (@ALGaffoRheumMD) October 23, 2018
Emerging perspectives on the role of the microbiome...
Antibiotics are affecting our microbiome and our health, and also may impact autoimmune diseases, according to the director of the New York University Human Microbiome Program. @ACRheum #rheumatologist #ACR18 #rheum https://t.co/y6ENQvaiiX— Medical Meeting News (@MedMtgNews) October 22, 2018
First three years of life decisive to your adult microbiome #ACR18 pic.twitter.com/sPNBJKhlL7— Jose Campos (@JoseCamposMD) October 21, 2018
We don’t have to tell you – getting a #lupus diagnosis is challenging. We shared some insights about how primary care providers diagnose lupus at #ACR18 today. https://t.co/Z6bujW6fWU pic.twitter.com/LHFvafbFrj— Lupus Foundation of America (@LupusOrg) October 23, 2018
Health tip for #lupus patients from last week’s #ACR18 conference: When using a health tracker, find a buddy to do it with. Research shows that people stick with it longer & benefit more with incentive from friends or a support group. Thanks to @ACRheum for this informative week! pic.twitter.com/BtfoCiSFQE— Lupus LA (@LupusLA) October 30, 2018
Phase III, randomized, db, pc trial with 405 pts. showing that #abatacept failed in pts. with #lupus #Nephritis #ACR18— S. Tomaras (@SteliosTomaras) October 26, 2018
For patients with ankylosing spondylitis, secukinumab is well tolerated, and no new safety concerns emerged in NCT01863732, a 3-year extension study. https://t.co/ODU2cSv5oV #ACR18— Medscape Rheum (@MedscapeRheum) October 27, 2018
Three New Treatments for #Osteoarthritis: Updates From #ACR18 https://t.co/RiBTDWfWVo— Rheumatology Network (@RheumatologyNet) October 29, 2018
Greater hip abductor strength confers additional benefits over and above quadriceps strength in persons with knee #osteoarthritis #ACR18 pic.twitter.com/RIp2XacNYE— David Hunter (@ProfDavidHunter) October 21, 2018
Just 5 minutes a day of moderate to vigorous walking can lower the risk for total knee replacement by 16% over 5 years in patients with knee osteoarthritis. https://t.co/KjxNwvVCK5 #ACR18— Medscape (@Medscape) November 4, 2018
Rheumatoid arthritis and its comorbidities...
Fascinating: where rheumatoid arthritis and interstitial lung disease come together. A GoF promoter varianthttps://t.co/NisDzzX9vN @NEJM— Eric Topol (@EricTopol) October 20, 2018
Implications for #RA screening; another outstanding outgrowth of the GWAS era #ACR18 @ACRheum
★ editorial by @Pkgg77 E Gravallese pic.twitter.com/WlhvVYbJJS
Findings of our study presented at #ACR18 highlights the importance addressing mental health and considering trauma-informed care in children w/ #arthritis. Thanks, @HealioRheum for covering. https://t.co/RAuQXYEX4s— Tamar Rubinstein (@TamarPedsRheum) November 4, 2018
#PsoriaticArthritis is not just RA with skin involvement.— CreakyJoints.org (@CreakyJoints) October 27, 2018
“We’re identifying more and more differences between psoriatic arthritis and #RheumatoidArthritis"- Alexis Ogdie, MD.
Read more learnings from #ACR18: https://t.co/9lp1TgKxB3 #Arthritis365 pic.twitter.com/5rkaKlhlck
...as well as the potential for alternative therapies.
Excited to be giving the lecture for the Lee C. Howley Sr. Prize for Arthritis Research at 2:30pm today at #ACR18! Many thanks to the @ArthritisFdn for their support of our work on new regenerative therapies for #arthritis. pic.twitter.com/l2KhdpyRRx— Farshid Guilak (@Farsh_G) October 21, 2018
ACR18 Insights >>> Published by MD Mag in Twitter: Both in combination with methotrexate and as a monotherapy, etanercept demonstrated better psoriatic #arthritis tre… https://t.co/oRFeymn20L https://t.co/2EVrYOf4wi #ACR18 #LucidQuest #followthepatient pic.twitter.com/6dl3Swjuc8— Dr Timos Papagatsias (@_timos_) October 26, 2018
The annual Great Debate focused on hydroxychloroquine dosing for systemic lupus erythematosus…
50% of SLE patients who are told they have HCQ retinopathy may actually have a mimicking retinal pathology. Second opinion by retinal specialist critical before stopping drug. #ACR18 #GreatDebate pic.twitter.com/IdC1UAePbq— Maximilian Konig (@maxfkonig) October 21, 2018
New this year was increased emphasis on patient perspectives…
This is my fifth year at ACR and it’s exciting to see patients incorporated into the conference more and more each year. This year, for the first time, Patient Perspective Posters! #ACR18 pic.twitter.com/cyUUOzsHXv— Mariah Leach (@MariahForward) October 21, 2018
So wonderful to see @steveston_gal sharing her patient perspective poster at #ACR18 @Arthritis_ARC @ACEJointHealth @LLi_1 @CherylKoehn @cath_back pic.twitter.com/oRiAxT6uBz— Alison Hoens (@PhysioKTBroker) October 21, 2018
Our friends @Arthritis_ARC and @steveston_gal are at #ACR18 sharing their views on Improved Quality of Life with Patient Engagement in Research. @CherylKoehn @chroniceileen @ArthritisNetwrk @ACRheum @PhysioKTBroker @VCHResearch @CHEOSNews @Arthritis_UBC @LLi_1 @ATricco @anetto pic.twitter.com/HwgxLf0pIh— JointHealth (@ACEJointHealth) October 21, 2018
All in all, it was a productive meeting! The 2019 ACR/ARHP Annual Meeting is scheduled to take place Nov. 8-13 in Atlanta, Georgia.